AIDS 2026: Co-Chairs' Choice
Chairs
Speakers
Eugene Ruzagira
MRC/UVRI and LSHTM Uganda Research Unit
Uptake, persistence and preference for long-acting injectable versus oral PrEP among Mobile Men in Uganda and South Africa: primary user effectiveness and implementation outcomes in the Mobile Men trial
- presentation-slides_306.pptx (3.91 MB)
Elise Lankiewicz
amfAR
Measuring PEPFAR disruptions at scale: Results from a 46-country implementing partner survey
- presentation-slides_307.pptx (2.25 MB)
Sharana Mahomed
CAPRISA
Safety and preliminary efficacy of 6-monthly subcutaneous CAP256V2LS plus VRC07-523LS for HIV prevention in African women: results of the CAPRISA 012C phase 2 randomised controlled trial
- presentation-slides_308.pptx (3.73 MB)
Mutsa Bwakura Dangarembizi
University of Zimbabwe Clinical Research Centre
Every-8-weeks injectable cabotegravir and rilpivirine is superior to daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir in adolescents living with HIV in sub-Saharan Africa: LATA 96-week results
- presentation-slides_309.pptx (1.73 MB)
Amy Colson
Community Resource Initiative
Once-weekly oral islatravir/lenacapavir (ISL/LEN) versus daily standard-of-care therapy in virologically suppressed adults with HIV-1: week 48 results of the ISLEND-2 phase 3 trial
- presentation-slides_310.pptx (318.67 KB)
Draurio Barreira
Ministry of Health
Beatriz Grinsztejn
Fiocruz/INI
Claudia Cortes
Universidad de Chile
Mutsa Bwakura Dangarembizi
University of Zimbabwe Clinical Research Centre
Amy Colson
Community Resource Initiative
Elise Lankiewicz
amfAR
Sharana Mahomed
CAPRISA
Eugene Ruzagira
MRC/UVRI and LSHTM Uganda Research Unit
Q&A and conclusion
Beatriz Grinsztejn
Fiocruz/INI
Jean William Pape
Les Centres GHESKIO
IAS President’s Award
- presentation-slides_311.pptx (2.8 MB)